CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Mar. 31, 2016
ASSETS
Cash and cash equivalents	$ 3,793,502	$ 9,270,010
Accounts receivable, net of allowance for doubtful accounts of $671,000 and $601,000 at September 30, 2016 and March 31, 2016, respectively	4,578,114	3,392,941
Other receivables	290,941	581,213
Due from affiliates	20,052	20,505
Prepaid expenses and other current assets	430,278	293,828
Total current assets	9,112,887	13,558,497
Deferred financing costs	0	37,926
Property and equipment, net	1,302,667	1,247,973
Restricted cash	530,000	530,000
Intangible assets, net	2,162,895	2,353,212
Goodwill	1,622,483	1,622,483
Other assets	221,979	216,442
TOTAL ASSETS	14,952,911	19,566,533
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' (DEFICIT) EQUITY
Accounts payable and accrued liabilities	4,544,711	4,572,307
Medical liabilities	2,069,392	2,670,709
Lines of credit	201,264	188,764
Total current liabilities	6,815,367	7,431,780
Warrant liability	1,477,778	2,811,111
Deferred rent liability	819,375	728,877
Deferred tax liability	43,479	43,479
Total liabilities	9,155,999	11,015,247
COMMITMENTS AND CONTINGENCIES
MEZZANINE EQUITY [Abstract]
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B); 1,111,111 issued and outstanding Liquidation preference of $9,999,999	7,077,778	7,077,778
STOCKHOLDERS' (DEFICIT) EQUITY
Common Stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 and 5,876,852 shares issued and outstanding as of September 30, 2016 and March 31, 2016, respectively	6,033	5,876
Additional paid-in-capital	24,190,118	23,524,517
Accumulated deficit	(31,358,231)	(28,684,565)
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	(3,277,335)	(1,269,427)
Non-controlling interest	1,996,469	2,742,935
Total stockholders' (deficit) equity	(1,280,866)	1,473,508
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	14,952,911	19,566,533
Series B Preferred Stock [Member]
STOCKHOLDERS' (DEFICIT) EQUITY
Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A); 555,555 issued and outstanding Liquidation preference of $4,999,995	$ 3,884,745	$ 3,884,745